“Brain healing” is one of those phrases that can make smart people stop asking questions. We don’t. Today we put two compounds under a bright light and let the evidence, the mechanisms, and the missing pieces speak for themselves: Dihexa and Cerebrolysin. Both get framed online as tools for cognition, recovery, and neuroprotection, but they live in very different worlds when you look at data quality and real-world oversight.

We start with Dihexa, the synthetic compound often called a “synapse builder.” We walk through synaptogenesis, dendritic spines, and why Alzheimer’s researchers care so much about connectivity loss. Then we slow down and do the part most posts skip: what animal studies can show, what they can’t, and why “more connections” is not automatically a healthier brain. We also face the uncomfortable realities head-on: no completed controlled human clinical trials, uncertain sourcing in the research-chemical marketplace, and a mechanism tied to HGF c-Met signaling, a pathway deeply studied in cancer biology. We even cover a key 2025 retraction and what that does to the tidy mechanism story.

Then we pivot to Cerebrolysin, a porcine brain peptide mixture that has been used internationally for decades and studied in dozens of randomized controlled trials across traumatic brain injury, stroke recovery, and dementia. The results are substantial but mixed, including a Cochrane review that raises real doubts in stroke outcomes, plus trial-quality and funding concerns that belong in any honest review. We also highlight the most concrete safety note clinicians watch for: lowered seizure threshold in people prone to seizures.

If you want a smarter way to think about peptides, biohacking, and brain health, come listen, share it with a friend, and subscribe. If the show helps you, leave a review so more people learn to question the headline and go looking for the mechanism underneath it.